An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles
Kojic acid (KA) as tyrosinase inhibitor shows insufficient skin penetration and several adverse events due topical administration. KA solid lipid nanoparticles (KA-SLNs) were prepared using high speed homogenisation followed by ultra-probe sonication method for improve its effectiveness.KA-SLNs was...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Artificial Cells, Nanomedicine, and Biotechnology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21691401.2020.1770271 |
| _version_ | 1827181449124511744 |
|---|---|
| author | Khadijeh Khezri Majid Saeedi Katayoun Morteza-Semnani Jafar Akbari Seyyed Sohrab Rostamkalaei |
| author_facet | Khadijeh Khezri Majid Saeedi Katayoun Morteza-Semnani Jafar Akbari Seyyed Sohrab Rostamkalaei |
| author_sort | Khadijeh Khezri |
| collection | DOAJ |
| description | Kojic acid (KA) as tyrosinase inhibitor shows insufficient skin penetration and several adverse events due topical administration. KA solid lipid nanoparticles (KA-SLNs) were prepared using high speed homogenisation followed by ultra-probe sonication method for improve its effectiveness.KA-SLNs was optimised by Glyceryl mono-stearate (GMS) and Cholesterol (Chol) as lipid excipients and span 60 (SP 60) and Tween 20 (Tw 20) as co-emulsifiers (particle size 156.97 ± 7.15 nm, encapsulation efficiency 59.02 ± 0.74%, drug loading 14.755 ± 1.63%, polydispersity index (PDI) of 0.388 ± 0.004 and zeta potential (ZP) of -27.67 ± 1.89 mV). Optimum formulation (KA-SLN3 dispersion) was stable at 4 and 25 °C for 3 months. Also, TEM image confirmed these results. The results of XRD, DSC and ATR-FTIR analysis indicated that KA was well encapsulated within the SLNs either in molecularly dispersed state and stabilised in amorphous form and there was no chemical interaction between drug and other ingredients. Controlled release was achieved with this formulation. KA-SLN3 dispersion have more tyrosinase inhibition potency in comparison with pure KA. Also, the results of the ex vivo and in vitro percutaneous absorption show that KA-SLN3 dispersion improved percutaneous delivery of KA as a promising and potential novel topical preparation and might open new avenues for treatment of hyperpigmentation disorders. |
| first_indexed | 2024-03-13T01:40:29Z |
| format | Article |
| id | doaj.art-2d1a06b6955b45d898c517f046088926 |
| institution | Directory Open Access Journal |
| issn | 2169-1401 2169-141X |
| language | English |
| last_indexed | 2025-03-21T05:46:59Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Artificial Cells, Nanomedicine, and Biotechnology |
| spelling | doaj.art-2d1a06b6955b45d898c517f0460889262024-07-23T18:44:31ZengTaylor & Francis GroupArtificial Cells, Nanomedicine, and Biotechnology2169-14012169-141X2020-01-0148184185310.1080/21691401.2020.1770271An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticlesKhadijeh Khezri0Majid Saeedi1Katayoun Morteza-Semnani2Jafar Akbari3Seyyed Sohrab Rostamkalaei4Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, IranDepartment of Pharmaceutics, Faculty of Pharmacy, Islamic Azad University, Ayatollah Amoli Branch, Amol, IranKojic acid (KA) as tyrosinase inhibitor shows insufficient skin penetration and several adverse events due topical administration. KA solid lipid nanoparticles (KA-SLNs) were prepared using high speed homogenisation followed by ultra-probe sonication method for improve its effectiveness.KA-SLNs was optimised by Glyceryl mono-stearate (GMS) and Cholesterol (Chol) as lipid excipients and span 60 (SP 60) and Tween 20 (Tw 20) as co-emulsifiers (particle size 156.97 ± 7.15 nm, encapsulation efficiency 59.02 ± 0.74%, drug loading 14.755 ± 1.63%, polydispersity index (PDI) of 0.388 ± 0.004 and zeta potential (ZP) of -27.67 ± 1.89 mV). Optimum formulation (KA-SLN3 dispersion) was stable at 4 and 25 °C for 3 months. Also, TEM image confirmed these results. The results of XRD, DSC and ATR-FTIR analysis indicated that KA was well encapsulated within the SLNs either in molecularly dispersed state and stabilised in amorphous form and there was no chemical interaction between drug and other ingredients. Controlled release was achieved with this formulation. KA-SLN3 dispersion have more tyrosinase inhibition potency in comparison with pure KA. Also, the results of the ex vivo and in vitro percutaneous absorption show that KA-SLN3 dispersion improved percutaneous delivery of KA as a promising and potential novel topical preparation and might open new avenues for treatment of hyperpigmentation disorders.https://www.tandfonline.com/doi/10.1080/21691401.2020.1770271Kojic acidHyperpigmentation disordersTyrosinaseSolid lipid Nanoparticles |
| spellingShingle | Khadijeh Khezri Majid Saeedi Katayoun Morteza-Semnani Jafar Akbari Seyyed Sohrab Rostamkalaei An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles Artificial Cells, Nanomedicine, and Biotechnology Kojic acid Hyperpigmentation disorders Tyrosinase Solid lipid Nanoparticles |
| title | An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles |
| title_full | An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles |
| title_fullStr | An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles |
| title_full_unstemmed | An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles |
| title_short | An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles |
| title_sort | emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders kojic acid solid lipid nanoparticles |
| topic | Kojic acid Hyperpigmentation disorders Tyrosinase Solid lipid Nanoparticles |
| url | https://www.tandfonline.com/doi/10.1080/21691401.2020.1770271 |
| work_keys_str_mv | AT khadijehkhezri anemergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT majidsaeedi anemergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT katayounmortezasemnani anemergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT jafarakbari anemergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT seyyedsohrabrostamkalaei anemergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT khadijehkhezri emergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT majidsaeedi emergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT katayounmortezasemnani emergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT jafarakbari emergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles AT seyyedsohrabrostamkalaei emergingtechnologyinlipidresearchfortargetinghydrophilicdrugstotheskininthetreatmentofhyperpigmentationdisorderskojicacidsolidlipidnanoparticles |